Goldman Sachs Initiates Coverage On Phathom Pharmaceuticals with Neutral Rating, Announces $32 Price Target

Goldman Sachs initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral rating and a $32 price target.

Benzinga · 11/19/2019 11:39

Goldman Sachs initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral rating and a $32 price target.